MedTrace Logo

CelAgace™ OraRinse Solution for Treatment of Candidiasis

NCT03250923 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-02-09

No results posted yet for this study

Summary

CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.

Conditions

  • Candidiasis, Oral

Interventions

DRUG

silver citrate complex and acemannan

Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan

Sponsors & Collaborators

Principal Investigators

  • Jacqueline M. Plemons, DDS, MS · Texas A&M University College of Dentistry

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2024-09-30
Completion
2025-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03250923 on ClinicalTrials.gov